Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test

SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.

Click here to view original post